@article{oai:nagoya.repo.nii.ac.jp:00028467,
 author = {Matsuhisa, Takaharu and Takahashi, Noriyuki and Nakaguro, Masato and Sato, Motoki and Inoue, Eri and Teshigawara, Shiho and Ozawa, Yukihiro and Kondo, Takeshi and Nakamura, Shigeo and Sato, Juichi and Ban, Nobutaro},
 issue = {3},
 journal = {Nagoya Journal of Medical Science},
 month = {Aug},
 note = {TAFRO syndrome is a novel disease concept characterized by Thrombocytopenia, Anasarca, myelo-Fibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and a histopathological pattern of atypical Castleman’s disease. A 58-year-old man was diagnosed as TAFRO syndrome by clinical and histopathological findings. After receiving intensive immunosuppressive therapy, his thrombocytopenia and anasarca had not improved. He developed complications such as methicillin-resistant Staphylococcus aureus sepsis, gastrointestinal bleeding, peritonitis caused by Stenotrophomonas maltophilia, gastrointestinal perforation, and disseminated candidiasis resulting in death. Autopsy revealed disseminated candidiasis and hemophagocytic lymphohistiocytosis, with no evidence of TAFRO syndrome. During treatment, we regarded his lasting thrombocytopenia and anasarca as insufficient control of TAFRO syndrome. However, the autopsy revealed that thrombocytopenia was caused by secondary hemophagocytic lymphohistiocytosis caused by over-immunosuppression. We reviewed the published literature to identify indicators of adequate treatment, which suggested improvement of platelet count and anasarca several weeks after initial therapy. This indicated that we could not depend on the platelet count and anasarca in acute medical care after initial treatment. We should treat TAFRO syndrome based on patients’ clinical status and obviate the risk of treatment-related complications caused by over-immunosuppression.},
 pages = {519--528},
 title = {Fatal case of TAFRO syndrome associated with over-immunosuppression: a case report and review of the literature},
 volume = {81},
 year = {2019}
}